PDF herunterladen
Semin Respir Crit Care Med 2018; 39(01): 091-099
DOI: 10.1055/s-0037-1607391
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Diagnosis and Management of Severe Asthma

Kian Fan Chung
1   Department of Respiratory Medicine, Airways Disease, National Heart & Lung Institute, Imperial College London, United Kingdom
2   Biomedical Research Unit, Royal Brompton & Harefield NHS Trust, London, United Kingdom
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
10. Februar 2018 (online)

    Lizenzen und Reprints

Abstract

Severe therapy-resistant asthma has been defined as “asthma which requires treatment with high dose inhaled corticosteroids (ICSs) plus a second controller (and/or systemic corticosteroids) to prevent it from becoming ‘uncontrolled’ or which remains ‘uncontrolled’ despite this therapy”. Patients who usually present with ‘difficult-to-treat asthma’ should first be assessed to determine whether he/she has asthma with the exclusion of other diagnoses and if so, whether the asthma can be classified as severe therapy-resistant. This necessitates an assessment of adherence to medications, confounding factors, and comorbidities. Increasingly, management of severe therapy-resistant asthma will be helped by the determination of phenotypes to optimize responses to existing and new therapies. Severe asthma patients are usually on a combination of high dose ICS and long-acting β-agonist (LABA) and, in addition, are often on a maintenance dose of oral corticosteroids. Phenotyping can be informed by measuring blood eosinophil counts and the level of nitric oxide in exhaled breath, and the use of sputum granulocytic counts. Severe allergic asthma and severe eosinophilic asthma are two defined phenotypes for which there are efficacious targeted biologic therapies currently available, namely anti-immunoglobulin E (IgE) and anti-interleukin (IL)-5 antibodies, respectively. Further progress will be realized with the definition of noneosinophilic or non-T2 phenotypes. It will be important for patients with severe asthma to be ultimately investigated and managed in specialized severe asthma centers.

Keywords

severe asthma - difficult-to-treat asthma - phenotyping - management of asthma - severe eosinophilic asthma - neutrophilic asthma - T2-high - T2-low - exhaled nitric oxide
 

  • References

  • 1 Bousquet J, Mantzouranis E, Cruz AA. , et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126 (05) 926-938
    CrossrefPubMedGoogle Scholar
  • 2 Reddel HK, Taylor DR, Bateman ED. , et al; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180 (01) 59-99
    CrossrefPubMedGoogle Scholar
  • 3 Chung KF, Godard P, Adelroth E. , et al; European Respiratory Society. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. Eur Respir J 1999; 13 (05) 1198-1208
    PubMedGoogle Scholar
  • 4 American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000; 162 (06) 2341-2351
    CrossrefPubMedGoogle Scholar
  • 5 Chung KF, Wenzel SE, Brozek JL. , et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43 (02) 343-373
    Google Scholar
  • 6 Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015; 135 (04) 896-902
    CrossrefPubMedGoogle Scholar
  • 7 Accordini S, Bugiani M, Arossa W. , et al. Poor control increases the economic cost of asthma. A multicentre population-based study. Int Arch Allergy Immunol 2006; 141 (02) 189-198
    CrossrefPubMedGoogle Scholar
  • 8 O'Neill S, Sweeney J, Patterson CC. , et al; British Thoracic Society Difficult Asthma Network. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax 2015; 70 (04) 376-378
    CrossrefPubMedGoogle Scholar
  • 9 Sin DD, Miravitlles M, Mannino DM. , et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J 2016; 48 (03) 664-673
    CrossrefPubMedGoogle Scholar
  • 10 Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF. ; Asthma and Allergy Research Group of the National Heart and Lung Institute. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003; 22 (03) 478-483
    CrossrefPubMedGoogle Scholar
  • 11 Radhakrishna N, Tay TR, Hore-Lacy F, Hoy R, Dabscheck E, Hew M. Profile of difficult to treat asthma patients referred for systematic assessment. Respir Med 2016; 117: 166-173
    CrossrefPubMedGoogle Scholar
  • 12 Shaw DE, Sousa AR, Fowler SJ. , et al; U-BIOPRED Study Group. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J 2015; 46 (05) 1308-1321
    CrossrefPubMedGoogle Scholar
  • 13 Moore WC, Bleecker ER, Curran-Everett D. , et al; National Heart, Lung, Blood Institute's Severe Asthma Research Program. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119 (02) 405-413
    CrossrefPubMedGoogle Scholar
  • 14 Sweeney J, Patterson CC, Menzies-Gow A. , et al; British Thoracic Society Difficult Asthma Network. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax 2016; 71 (04) 339-346
    CrossrefPubMedGoogle Scholar
  • 15 Radhakrishna N, Tay TR, Hore-Lacy F. , et al. Validated questionnaires heighten detection of difficult asthma comorbidities. J Asthma 2017; 54 (03) 294-299
    CrossrefPubMedGoogle Scholar
  • 16 Tay TR, Radhakrishna N, Hore-Lacy F. , et al. Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology 2016; 21 (08) 1384-1390
    CrossrefPubMedGoogle Scholar
  • 17 Clark VL, Gibson PG, Genn G, Hiles SA, Pavord ID, McDonald VM. Multidimensional assessment of severe asthma: A systematic review and meta-analysis. Respirology 2017
    PubMedGoogle Scholar
  • 18 Tay TR, Lee J, Radhakrishna N. , et al. A Structured Approach to Specialist-referred Difficult Asthma Patients Improves Control of Comorbidities and Enhances Asthma Outcomes. J Allergy Clin Immunol Pract 2017; 5 (04) 956-964.e3
    CrossrefPubMedGoogle Scholar
  • 19 Gibeon D, Heaney LG, Brightling CE. , et al; British Thoracic Society Difficult Asthma Network. Dedicated severe asthma services improve health-care use and quality of life. Chest 2015; 148 (04) 870-876
    CrossrefPubMedGoogle Scholar
  • 20 Sweeney J, Brightling CE, Menzies-Gow A, Niven R, Patterson CC, Heaney LG. ; British Thoracic Society Difficult Asthma Network. Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry. Thorax 2012; 67 (08) 754-756
    CrossrefPubMedGoogle Scholar
  • 21 Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009; 180 (09) 817-822
    CrossrefPubMedGoogle Scholar
  • 22 Murphy AC, Proeschal A, Brightling CE. , et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax 2012; 67 (08) 751-753
    CrossrefPubMedGoogle Scholar
  • 23 Williams LK, Peterson EL, Wells K. , et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol 2011; 128 (06) 1185-1191.e2
    CrossrefPubMedGoogle Scholar
  • 24 McNicholl DM, Stevenson M, McGarvey LP, Heaney LG. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med 2012; 186 (11) 1102-1108
    CrossrefPubMedGoogle Scholar
  • 25 Pilcher J, Holliday M, Ebmeier S. , et al. Validation of a metered dose inhaler electronic monitoring device: implications for asthma clinical trial use. BMJ Open Respir Res 2016; 3 (01) e000128
    CrossrefPubMedGoogle Scholar
  • 26 Pilcher J, Shirtcliffe P, Patel M. , et al. Three-month validation of a turbuhaler electronic monitoring device: implications for asthma clinical trial use. BMJ Open Respir Res 2015; 2 (01) e000097
    PubMedGoogle Scholar
  • 27 Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18 (05) 716-725
    CrossrefPubMedGoogle Scholar
  • 28 Chung KF. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. J Intern Med 2016; 279 (02) 192-204
    CrossrefPubMedGoogle Scholar
  • 29 Nair P, Dasgupta A, Brightling CE, Chung KF. How to diagnose and phenotype asthma. Clin Chest Med 2012; 33 (03) 445-457
    CrossrefPubMedGoogle Scholar
  • 30 Chung KF. Inflammatory biomarkers in severe asthma. Curr Opin Pulm Med 2012; 18 (01) 35-41
    CrossrefPubMedGoogle Scholar
  • 31 Haldar P, Pavord ID, Shaw DE. , et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178 (03) 218-224
    CrossrefPubMedGoogle Scholar
  • 32 Lefaudeux D, De Meulder B, Loza MJ. , et al. U-BIOPRED Study Group. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol 2017; 139 (06) 1797-1807
    CrossrefPubMedGoogle Scholar
  • 33 Moore WC, Meyers DA, Wenzel SE. , et al; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181 (04) 315-323
    CrossrefPubMedGoogle Scholar
  • 34 Cowan DC, Taylor DR, Peterson LE. , et al. Biomarker-based asthma phenotypes of corticosteroid response. J Allergy Clin Immunol 2015; 135 (04) 877-83.e1
    CrossrefPubMedGoogle Scholar
  • 35 Schleich FN, Chevremont A, Paulus V. , et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J 2014; 44 (01) 97-108
    CrossrefPubMedGoogle Scholar
  • 36 Price DB, Rigazio A, Campbell JD. , et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 2015; 3 (11) 849-858
    CrossrefPubMedGoogle Scholar
  • 37 de Groot JC, Storm H, Amelink M. , et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res 2016; 2 (02) 00100-02015
    PubMedGoogle Scholar
  • 38 Buhl R, Humbert M, Bjermer L. , et al; and the expert group of the European Consensus Meeting for Severe Eosinophilic Asthma. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J 2017; 49 (05) 49
    CrossrefPubMedGoogle Scholar
  • 39 Chung KF, Adcock IM. Clinical phenotypes of asthma should link up with disease mechanisms. Curr Opin Allergy Clin Immunol 2015; 15 (01) 56-62
    CrossrefPubMedGoogle Scholar
  • 40 Woodruff PG, Modrek B, Choy DF. , et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180 (05) 388-395
    CrossrefPubMedGoogle Scholar
  • 41 Pavlidis SLM, Baribaud F, Kuo C-H. , et al. Th2 subsetting of U-BIOPRED asthma subjects based on airway transciptomic profiles. Eur Respir J 2015; 46: OA1772 . Doi: 10.183/13993003.congress-2015
    PubMedGoogle Scholar
  • 42 Kuo CS, Pavlidis S, Loza M. , et al; U-BIOPRED Project Team ‡. A Transcriptome-driven Analysis of Epithelial Brushings and Bronchial Biopsies to Define Asthma Phenotypes in U-BIOPRED. Am J Respir Crit Care Med 2017; 195 (04) 443-455
    CrossrefPubMedGoogle Scholar
  • 43 Macedo P, Hew M, Torrego A. , et al. Inflammatory biomarkers in airways of patients with severe asthma compared with non-severe asthma. Clin Exp Allergy 2009; 39 (11) 1668-1676
    CrossrefPubMedGoogle Scholar
  • 44 Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160 (5 Pt 1): 1532-1539
    CrossrefPubMedGoogle Scholar
  • 45 Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999; 353 (9171): 2213-2214
    CrossrefPubMedGoogle Scholar
  • 46 Moore WC, Hastie AT, Li X. , et al; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol 2014; 133 (06) 1557-63.e5
    CrossrefPubMedGoogle Scholar
  • 47 Fahy JV, Kim KW, Liu J, Boushey HA. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 1995; 95 (04) 843-852
    CrossrefPubMedGoogle Scholar
  • 48 Kuo CS, Pavlidis S, Loza M. , et al; U-BIOPRED Study Group. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J 2017; 49 (02) 49
    CrossrefPubMedGoogle Scholar
  • 49 Nguyen LT, Lim S, Oates T, Chung KF. Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma. Respir Med 2005; 99 (02) 200-207
    CrossrefPubMedGoogle Scholar
  • 50 O'Byrne PM, Metev H, Puu M. , et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2016; 4 (10) 797-806
    CrossrefPubMedGoogle Scholar
  • 51 Simpson JL, Phipps S, Baines KJ, Oreo KM, Gunawardhana L, Gibson PG. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur Respir J 2014; 43 (04) 1067-1076
    CrossrefPubMedGoogle Scholar
  • 52 Rossios CPS, Hoda U, Kuo C. , et al. Sputum transcriptomics reveal up-regulation of IL-1 receptor family members in severe asthma. J Allergy Clin Immunol 2017 ; In press
    PubMedGoogle Scholar
  • 53 Hew M, Chung KF. Corticosteroid insensitivity in severe asthma: significance, mechanisms and aetiology. Intern Med J 2010; 40 (05) 323-334
    CrossrefPubMedGoogle Scholar
  • 54 Bateman ED, Boushey HA, Bousquet J. , et al; GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170 (08) 836-844
    CrossrefPubMedGoogle Scholar
  • 55 Gibeon D, Batuwita K, Osmond M. , et al. Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI. Chest 2013; 143 (02) 406-414
    CrossrefPubMedGoogle Scholar
  • 56 Green RH, Brightling CE, McKenna S. , et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360 (9347): 1715-1721
    CrossrefPubMedGoogle Scholar
  • 57 Bel EH, Wenzel SE, Thompson PJ. , et al; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371 (13) 1189-1197
    CrossrefPubMedGoogle Scholar
  • 58 Nair P, Wenzel S, Rabe KF. , et al; ZONDA Trial Investigators. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med 2017; 376 (25) 2448-2458
    CrossrefPubMedGoogle Scholar
  • 59 Petsky HL, Cates CJ, Lasserson TJ. , et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67 (03) 199-208
    CrossrefPubMedGoogle Scholar
  • 60 Gaillard EA, McNamara PS, Murray CS, Pavord ID, Shields MD. Blood eosinophils as a marker of likely corticosteroid response in children with preschool wheeze: time for an eosinophil guided clinical trial?. Clin Exp Allergy 2015; 45 (09) 1384-1395
    CrossrefPubMedGoogle Scholar
  • 61 Wagener AH, de Nijs SB, Lutter R. , et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 2015; 70 (02) 115-120
    CrossrefPubMedGoogle Scholar
  • 62 Ortega HG, Liu MC, Pavord ID. , et al; MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371 (13) 1198-1207
    CrossrefPubMedGoogle Scholar
  • 63 Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. Chest 2016; 150 (04) 799-810
    CrossrefPubMedGoogle Scholar
  • 64 FitzGerald JM, Bleecker ER, Nair P. , et al; CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388 (10056): 2128-2141
    CrossrefPubMedGoogle Scholar
  • 65 Bleecker ER, FitzGerald JM, Chanez P. , et al; SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388 (10056): 2115-2127
    CrossrefPubMedGoogle Scholar
  • 66 Hanania NA, Wenzel S, Rosén K. , et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187 (08) 804-811
    CrossrefPubMedGoogle Scholar
  • 67 Kerstjens HA, Disse B, Schröder-Babo W. , et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011; 128 (02) 308-314
    CrossrefPubMedGoogle Scholar
  • 68 Kerstjens HA, Engel M, Dahl R. , et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367 (13) 1198-1207
    CrossrefPubMedGoogle Scholar
  • 69 Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet 2015; 386 (9998): 1086-1096
    CrossrefPubMedGoogle Scholar
  • 70 Chupp GL, Bradford ES, Albers FC. , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017; 5 (05) 390-400
    CrossrefPubMedGoogle Scholar
  • 71 Pretolani M, Bergqvist A, Thabut G. , et al. Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: Clinical and histopathologic correlations. J Allergy Clin Immunol 2017; 139 (04) 1176-1185
    CrossrefPubMedGoogle Scholar
  • 72 Burn J, Sims AJ, Keltie K. , et al. Procedural and short-term safety of bronchial thermoplasty in clinical practice: evidence from a national registry and Hospital Episode Statistics. J Asthma 2016; 1-8
    PubMedGoogle Scholar
  • 73 Chung KF. Airway microbial dysbiosis in asthmatic patients: A target for prevention and treatment?. J Allergy Clin Immunol 2017; 139 (04) 1071-1081
    CrossrefPubMedGoogle Scholar
  • 74 Gibson PG, Yang IA, Upham JW. , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390 (10095): 659-668
    CrossrefPubMedGoogle Scholar
  • 75 Brusselle GG, Vanderstichele C, Jordens P. , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013; 68 (04) 322-329
    CrossrefPubMedGoogle Scholar
  • 76 Zhang H, Gustafsson M, Nestor C, Chung KF, Benson M. Targeted omics and systems medicine: personalising care. Lancet Respir Med 2014; 2 (10) 785-787
    CrossrefPubMedGoogle Scholar